Protara Therapeutics stock (US87612E1064): Q1 earnings beat estimates with narrower loss

Protara Therapeutics reported Q1 2026 earnings on May 13, beating EPS estimates with a net loss of $17.78 million. Shares rose 0.97% to $5.20 on Nasdaq amid clinical updates.

Protara Therapeutics released its first quarter 2026 financial results on May 13, 2026, reporting a net loss of $17.78 million for the period ended March 31, 2026, compared to $11.91 million a year earlier, according to Marketscreener as of 05/13/2026. Basic loss per share was $0.31, improved from $0.29 year-over-year and beating consensus estimates of -$0.36 by $0.05, per MarketBeat as of 05/13/2026. The stock gained 0.97% to close at $5.20 on Nasdaq that day.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Protara Therapeutics, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology, rare diseases
• Key revenue drivers: Clinical-stage therapies
• Home exchange/listing venue: Nasdaq (TARA)
• Trading currency: USD

Protara Therapeutics: core business model

Protara Therapeutics is a clinical-stage biotech company focused on developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is an investigational cell-based immunotherapy derived from Streptococcus pyogenes, targeting lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). The company has no approved products and generates no revenue, relying on cash reserves to fund operations.

Protara in-licenses promising assets and advances them through clinical trials. TARA-002 received FDA Breakthrough Therapy Designation for LMs in pediatric patients, highlighting its potential in underserved areas. The business model centers on milestone payments, partnerships, and eventual commercialization or out-licensing.

Main revenue and product drivers for Protara Therapeutics

Development of TARA-002 drives Protara's pipeline value. In Q1 2026, the company advanced preparations for a Biologics License Application (BLA) submission following positive FDA interactions, as noted in its earnings release via Business Insider as of 05/13/2026. A virtual investor webinar on TARA-002 in LMs is scheduled for May 19, 2026.

Future revenue hinges on regulatory approvals and trial successes. The stock traded at $5.20 USD on 05/13/2026 on Nasdaq, according to MarketBeat as of 05/13/2026.

Industry trends and competitive position

The biotech sector faces funding challenges but sees demand for rare disease therapies. Protara's focus on LMs addresses a niche with limited options, positioning it favorably if TARA-002 succeeds. US investors track such firms for high-upside potential in oncology and pediatrics.

Conclusion

Protara Therapeutics' Q1 2026 results showed a controlled loss expansion amid pipeline progress on TARA-002. The EPS beat and upcoming BLA plans underscore clinical momentum. Investors monitor FDA interactions and trial data for US-listed biotech exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.